PHARMA MAR, S.A. «...1112131415...» Page 12 out of 22 28/02/2022 18:01 PHARMA MAR, S.A. Annual report on directors´ remunerations La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2021 Register number: 14634 28/02/2022 18:01 PHARMA MAR, S.A. Annual corporate governance report La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2021 Register number: 14632 28/02/2022 17:52 PHARMA MAR, S.A. Other relevant information - On business and financial situation - On corporate governance The Company reports draw up of the Annual Financial Statements 2021, a proposal for a dividend, an amendment to the Board of Directors Regulations, and a conference call with analysts and investors. Register number: 14625 28/02/2022 17:42 PHARMA MAR, S.A. On business and financial situation The Company sends press release regarding year 2021 results together with financial report. Register number: 14619 28/02/2022 17:38 PHARMA MAR, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del segundo semestre de 2021 Register number: 14618 22/02/2022 17:19 PHARMA MAR, S.A. Other relevant information The Company reports that will host a key opinion leader (KOL) webinar on Small Cell Lung Cancer (SCLC) on March 9th, 2022, at 19.00 CET Register number: 14177 11/01/2022 08:29 PHARMA MAR, S.A. Other relevant information The Company reports that the publication titled “Pre-clinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19” has been published in the Life Science Alliance journal. Register number: 13557 05/01/2022 11:44 PHARMA MAR, S.A. Liquidity and counterparty agreements The Company reports details of the operations of the Liquidity Agreement between 01/10/2021 and 31/12/2021 Register number: 13523 22/12/2021 08:28 PHARMA MAR, S.A. On business and financial situation The Company announces the signature of a license and commercialization agreement with Eczacibasi Pharmaceuticals Marketing Co. to commercialize the anticancer drug lurbinectedin in Turkey. Register number: 13305 13/12/2021 08:26 PHARMA MAR, S.A. On business and financial situation The Company announces the initiation of a confirmatory Phase III clinical trial, LAGOON, evaluating Zepzelca® (lurbinectedin) for the treatment of patients with relapsed Small Cell Lung Cancer (SCLC). Register number: 13128 Page 12 out of 22 «...1112131415...»
